Published in Healthcare Mergers, Acquisitions and Ventures Week, February 11th, 2006
The company received $1 million in gross proceeds that was payable upon completion of that milestone. An additional $2 million in gross proceeds will be paid at the time the registration statement becomes effective.
"I am glad that ABPH met this milestone in an efficient and timely manner," said Denis O'Connor, CEO of Advanced BioPhotonics. "The proceeds will be used to continue the clinical validation necessary to fuel market adoption and revenue...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.